Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration.

ABSTRACT: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with a rising incidence. The most common therapeutic choice for HCC is transarterial chemoembolization (TACE). While the standard protocol of TACE adopts cisplatin, the application of cisplatin needs hydration before and after the procedure to alleviate adverse effects on kidney function. Miriplatin, a lipophilic platinum complex, enables the omission of periprocedural hydration compared to cisplatin-based TACE. This study aimed to compare the survival benefit between miriplatin-based TACE and cisplatin-based TACE. Briefly, a retrospective cohort study in a single hospital was designed. Patients with HCC complicated by vascular invasion or distant metastasis were excluded. Background variability was adjusted using a

SUBMITTER: Fujita K 

PROVIDER: S-EPMC11880689 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature